Skip to content

To study the irritation and allergic reaction of test products in Men and Women.

Evaluation of skin irritation and skin sensitization potential of Moisturex Baby Moisturizing Lotion and Moisturex Baby Shampoo using Human Repeat Insult Patch Test (HRIPT).IS 4011:2018 Guidelines - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076617
Enrollment
220
Registered
2024-11-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Moisturex Baby Shampoo: A series of dilutions will be applied on 5 – 10 participants and occluded. Patches will be removed at 24 hours and reactions graded at 48 hours. Then the highest

Sponsors

Sun Pharmaceutical Industries Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntary healthy men and women between 18 and 65 years with at least 50 participants having sensitive skin in the nasolabial area as confirmed by lactic acid sting test @ 2. Fitzpatrick skin type III to IV. 3. Having apparently healthy skin on test area. 4. For whom the Investigator considers that the compliance will be correct. 5. Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures. 6. Having signed a Consent Form. 7. Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study. 8. Willingness to avoid water contact (i.e.: swimming) or activity which cause sweating (i.e.: exercise, sauna etc), during the course of the study. 9. Should be able to read and write (in English, Hindi or local language). 10. Having valid proof of identity and age.

Exclusion criteria

Exclusion criteria: 1. Pregnancy (by UPT) and lactating women. 2. Scars, excessive terminal hair or tattoo on the studied area. 3. Dermatological infection/pathology on the level of studied area. 4. Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye). 5. Any clinically significant systemic or cutaneous disease, which may interfere with study procedures. 6. Chronic illness which may influence the outcome of the study. 7. Participants on any medical treatment either systemic or topical which may interfere with the performance of the study (presently or in the past 1 month). 8. Participant in an exclusion period or participating in another food, cosmetic or therapeutic trial.

Design outcomes

Primary

MeasureTime frame
Evaluation of cutaneous tolerance by dermatological scoring.Timepoint: Visit 1: ICD and inclusion or exclusion. Induction Phase: Patch application on Visit 1 (V1, V3,V5, V7, V9, V11, V13, V15, V17). Patch will be removed on Visit 2 (V2, V4, V6, V8, V10, V12,V14, V16, V18). Patch area will be clinically examined, graded and scored on Visit 3 (V3, V5, V7, V9, V11, V13, V15, V17, V19) Challenge Phase: Patch application will be on naïve sites on the back on V20; patch will be removed at V21 (24 hours).Scoring on V22 (48 hours), V23 (72 hours). V24 (96 hours).

Secondary

MeasureTime frame
NoneTimepoint: Nil

Countries

India

Contacts

Public ContactMs Preetha Paul

Sun Pharmaceuticals Industries Ltd.

bhavesh.lalan@sunpharma.com43241234

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026